The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas.

ABSTRACT:

Background

The prognostic role of epidermal growth factor receptor (EGFR) mutations in patients with lung adenocarcinomas remains controversial and the association between EGFR mutations and stage at the time of the initial diagnosis is debatable. In this study, we evaluated the association of EGFR mutations with stage at diagnosis in lung adenocarcinomas.

Materials and methods

We retrospectively analyzed 1004 consecutive patients who were diagnosed with lung adenocarcinomas and tested for EGFR mutations between June 2011 and December 2014.

Results

EGFR mutations were detected in 49.2% of 1004 patients with lung adenocarcinomas. In multivariable analysis, EGFR mutations were significantly associated with early stage disease (stage I to II) at diagnosis (odds ratio [OR

SUBMITTER: Cho J 

PROVIDER: S-EPMC5115811 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature